MICROPORT (00853) announced that on September 29, 2025, CRM Cayman, MicroPort CardioFlow, and MicroPort CardioFlow CRM Limited (the merger subsidiary) entered into a merger agreement. The merger subsidiary is an exempted limited company incorporated in the Cayman Islands and is an indirectly wholly-owned subsidiary of MicroPort CardioFlow. Under the merger agreement, MicroPort CardioFlow will acquire CRM Cayman through the merger subsidiary via a merger arrangement. Upon the merger becoming effective, CRM Cayman will become an indirectly wholly-owned subsidiary of MicroPort CardioFlow. As consideration, MicroPort CardioFlow will allot and issue certain new shares to shareholders of CRM Cayman (including MicroPort International Corp. Limited, an indirectly wholly-owned subsidiary of the company) at an issue price of HK$1.35 per share. Following completion of the merger, CRM Cayman and its subsidiaries will become indirect subsidiaries of MicroPort CardioFlow, and CRM Cayman, MicroPort CardioFlow and their respective subsidiaries will continue to be subsidiaries of the company. The announcement stated that the transaction described in the merger agreement aligns with the strategic development of MicroPort CardioFlow's business and will help MicroPort CardioFlow establish a globally positioned cardiac product platform with diversified products and product pipeline, achieving complementary synergistic effects. These synergistic effects will expand and diversify MicroPort CardioFlow's existing business, particularly in enhancing MicroPort CardioFlow's products and product pipeline, research and development capabilities, manufacturing capabilities, distribution channels, and market expansion in structural heart disease and cardiac rhythm disease solutions.